Verve Therapeutics lands $94m Series B

Verve Therapeutics, a biotech company focused on treating cardiovascular disease, has closed $94 million in Series B financing.

20 January 2021•1 min read

[data-article-body-skeleton]{display:none!important}

JavaScript is required to read this article. Please enable it in your browser and reload the page.

Healthcare Briefs